Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

ACR246, a first in next-generation 5T4-ADC, as a potential choice of treating 5T4-positive solid tumors.

Xi Jiao, Zhenwei Miao, Jing Gao et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15110

e15110 Background: 5T4 oncofetal antigen shows limited expression in normal adult tissues but highly expressed by many dif...

Association of deep learning CT response assessment and interpretable components with overall survival in advanced NSCLC: Validation in a trial of sasanlimab and a real-world dataset.

Chiharu Sako, Taly Schmidt, Chong Duan et al. Jun 01, 2025 pp. 1559-1559 10.1200/jco.2025.43.16_suppl.1559

1559 Background: Identifying advanced non–small cell lung cancer (aNSCLC) patients who derive long-term benefit from immune checkpoint inhibitors (ICIs) r...

The prognostic and predictive role of HER2 amplification/overexpression and <i>HER2</i> mutations in metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab/anti-EGFRs: An individual patient data pooled analysis of eight randomized trials.

Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto et al. Jun 01, 2025 pp. 3537-3537 10.1200/jco.2025.43.16_suppl.3537

3537 Background: HER2 amplification/overxpression (HER2-pos) is detected in the 5% of RAS/BRAF wild-type (wt) metastatic colorecta...

Efficacy and safety of post-mastectomy radiation therapy for patients with breast cancer after breast reconstruction: A retrospective multicenter cohort study (Reborn-03).

Wakako Tsuji, Shinsuke Sasada, Noriyuki Watanabe et al. Jun 01, 2025 pp. 579-579 10.1200/jco.2025.43.16_suppl.579

579 Background: A cornerstone of multidisciplinary treatment for breast cancer, breast reconstruction has recently been extended to high-risk patients wit...

The efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytes: Histological assessment of CD8+ T cell spatial features as predictive biomarkers.

Hiroaki Kanzaki, Takamasa Ishino, Sadahisa Ogasawara et al. Jun 01, 2025 pp. 4103-4103 10.1200/jco.2025.43.16_suppl.4103

4103 Background: The combination of atezolizumab and bevacizumab (Atez/Bev) has improved prognosis in advanced hepatocellular carcinoma (HCC), though its...

Pharmacologic and pharmacometric studies of factors affecting the pharmacokinetics and pharmacodynamics of antibody drug conjugate anetumab ravtansine in patients with solid tumors.

Li Chen, Andrew T. Lucas, Julie Dumond et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15024

e15024 Background: Anetumab ravtansine (AR) is an antibody-drug conjugate (ADC) containing the microtubule inhibitor DM4. ADC drugs have high interpatient...

Evaluation of p53 protein expression in endometrial carcinoma using immunohistochemistry: A study from Vietnam.

Thuan Minh Quang Tran, Dang Phan Hoang Nguyen, Dieu Nguyet Au et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17614

e17614 Background: The International Federation of Gynecology and Obstetrics (FIGO) 2023 recommends integrating molecular subtype evaluation into endometr...

From text to insight: Methods for validation of NLP-extracted real-world oncology data using a human-in-the-loop electronic review tool.

Elizabeth Eldridge, Elizabeth Trowbridge, Brian Berns et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23291

e23291 Background: Natural Language Processing (NLP) for extraction of oncology-specific data-phenotypes from free-text in electronic medical records (EMR...

Struma ovarii: An NCDB retrospective study of demographic and socioeconomic factors.

Abbi Gobel, Edie Gobel, Suraj Puvvadi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17590

e17590 Background: Struma ovarii malignant cancer (SOMC) is an extremely rare ovarian teratoma originating from aberrant thyroid tissue that can mimic thy...

Induction cadonilimab combined with chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A multicenter, single-arm, phase II trial.

Lin Ding, Shasha He, Jin Yang et al. Jun 01, 2025 pp. 5530-5530 10.1200/jco.2025.43.16_suppl.5530

5530 Background: Short-course weekly induction chemotherapy followed by chemoradiotherapy (CCRT) improves survival for locally advanced cervical cancer (L...

Phase 1/2 study of nivolumab and ipilimumab combined with gemcitabine, nab-paclitaxel, and adaptive stereotactic body radiotherapy in bordeline resectable, locally advanced or metastatic pancreatic cancer (LAPTOP).

Inna Markovna Chen, Mario Presti, Carsten Palnaes Hansen et al. Jun 01, 2025 pp. 4168-4168 10.1200/jco.2025.43.16_suppl.4168

4168 Background: This phase 1/2 study (NCT04247165) evaluated the safety and efficacy of combining nivolumab, ipilimumab, gemcitabine, nab-paclitaxel, and...

Comparative analysis of health disparities in prostate cancer patients with and without venous thromboembolism, and with and without anticoagulation therapy.

Tijin Mathew, Akshita Khosla, Rajashree Hariprasad et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17162

e17162 Background: Venous thromboembolism (VTE) in cancer is a commonly observed clinical complication. The risk of VTE is high in prostate cancer when co...

Perceptions, attitudes, and concerns about artificial intelligence applications in patients with cancer.

Enes Erul, Yusuf Aktekin, Şükrü Armanç Gümüştaş et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13626

e13626 Background: The use of artificial intelligence (AI) in oncology has increased rapidly, spanning applications such as pathology, radiology, diagnost...

Cardiovascular risk factor control and risk of future cardiovascular events in survivors of childhood cancer: A report from the St. Jude Lifetime cohort.

Stephanie B. Dixon, Yan Chen, Sedigheh Mirzaei et al. Jun 01, 2025 pp. 10065-10065 10.1200/jco.2025.43.16_suppl.10065

10065 Background: Modifiable cardiovascular risk factors (CVRFs; hypertension, diabetes, dyslipidemia) contribute to the excess health-related death in lo...

V-RULES: Real-world effectiveness and safety of CPX-351 in patients with secondary acute myeloid leukemia (AML).

Thomas William LeBlanc, Catherine Lai, Amir Ali et al. Jun 01, 2025 pp. 6520-6520 10.1200/jco.2025.43.16_suppl.6520

6520 Background: CPX-351 was approved for newly diagnosed (ND) therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC) following...

A simplified scoring system to predict in-hospital mortality of leukapheresis in patients with leukemia.

Barath Prashanth Sivasubramanian, Gagan Kumar, Achuta Kumar Guddati Jun 01, 2025 pp. 6575-6575 10.1200/jco.2025.43.16_suppl.6575

6575 Background: The 2019 consensus guidelines from the American Society for Apheresis recommend leukapheresis as a category II recommendation (acceptable...

Menopausal hormone therapy after a diagnosis of breast cancer in women with a <i>BRCA</i> pathogenic variant and risk of death.

Joanne Kotsopoulos, Marta Seca, Jan Lubiński et al. Jun 01, 2025 pp. 10506-10506 10.1200/jco.2025.43.16_suppl.10506

10506 Background: Use of menopausal hormone therapy (MHT) is contraindicated for women with a personal history of breast cancer. This topic is of importan...

Regional trends in disability adjusted life years (DALYs) and mortality of pancreatic cancer among older adults (70+): A global burden of disease study (1990–2021).

Nana Sardarova, Muhammad Ismail, Husnain Ahmad et al. Jun 01, 2025 pp. 11153-11153 10.1200/jco.2025.43.16_suppl.11153

11153 Background: Pancreatic cancer is a major health challenge, particularly for older adults, with significant regional disparities in its burden over t...

Efficacy of local therapy in Chinese patients with BCLC stage C hepatocellular carcinoma (HCC): A retrospective cohort study of 370 patients over six years.

Liwei Qin, Hu Liu, Junyan Zhang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16228

e16228 Background: Even though systemic therapy has been recommended as the standard of care for advanced HCC at Barcelona Clinic Liver Cancer (BCLC) stag...

Characterizing the prevalence and prognostic significance of MTAP loss in endemic nasopharyngeal cancer using immunohistochemistry (IHC) versus fluorescent in situ hybridization (FISH).

David Johnson, Brigette Ma, Yuk-Yu Chan et al. Jun 01, 2025 pp. 6052-6052 10.1200/jco.2025.43.16_suppl.6052

6052 Background: Methylthioadenosine phosphorylase (MTAP) loss has been associated with poor outcomes in various cancers, including nasopharyngeal carcino...

A real-world study on epidemiology, biomarker test results, clinical characteristics, and treatment patterns of unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma in China.

Yang Chen, Yi Xie, Lei Jiang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16013

e16013 Background: Gastric cancer is the fifth most common cancer and third leading cause of cancer-related death in China, with about 90% classified as a...

Irradiated tumor volume as a predictor of local recurrence and radionecrosis in lung cancer with brain metastases treated with stereotactic radiosurgery.

Andreas Koulouris, Oscar Grundberg, Marcus Skribek et al. Jun 01, 2025 pp. 2024-2024 10.1200/jco.2025.43.16_suppl.2024

2024 Background: Stereotactic radiosurgery (SRS) is a standard local treatment for brain metastases (BM), but it may result in local recurrence (LR) or ra...

First-line durvalumab with arterial chemotherapy in major portal invaded hepatocellular carcinoma: The phase 2 DurHope study with biomolecular analyses.

Ming Zhao, Ning Lyu, Junzhe Yi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16232

e16232 Background: Hepatocellular carcinoma (HCC) patients with Vp4 portal vein tumor thrombus (PVTT) have a poor prognosis and are underrepresented in gl...

Impact of demographic and socioeconomic factors on survival outcomes in patients with Waldenstrom macroglobulinemia: A SEER database analysis from 2000-2021.

Supriya Peshin, Asfand Yar Cheema, Mishaal Munir et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19046

e19046 Background: Waldenstrom Macroglobulinemia (WM) is a rare, indolent B-cell malignancy characterized by the overproduction of IgM monoclonal proteins...

An exploratory study of neoadjuvant tislelizumab combined with TP regimen for the comprehensive treatment of resectable locally advanced oral squamous cell carcinoma.

Xuan Su, Guannan Wang, Wenjie Huang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18034

e18034 Background: The landscape of neoadjuvant immunotherapy for resectable locally advanced head and neck squamous cell carcinoma has improved significa...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page